Saccharomyces boulardii: A Review of an Innovative Bio therapeutic Agent

Article English OPEN
McFarland, L. V. ; Bernasconi, P. (2011)
  • Publisher: Microbial Ecology in Health and Disease
  • Journal: Microbial Ecology in Health and Disease (issn: 1651-2235, eissn: 1651-2235)
  • Related identifiers: doi: 10.3402/mehd.v6i4.8126
  • Subject:
    mesheuropmc: digestive, oral, and skin physiology

Saccharomyces boulardii is a non-pathogenic yeast which has been used as both a preventive and therapeutic agent for the treatment of a variety of diarrhoeal diseases. The studies with animal models and evidence from human volunteers and patients indicate a profile which is effective in the therapy of diarrhoea and is remarkably safe for oral ingestion. The pharmacokinetic data demonstrate that S. boulardii reaches a steady-state concentration quickly and maintains a high stable level as long as the yeast is taken daily. Once the agent is discontinued, S. boulardii is quickly eliminated from the colon. Clinical trials studying antibiotic-associated diarrhoea, nasogastric-tube alimentation diarrhoea, Clostridium difficile-disease, acute diarrhoea and chronic diarrhoea in HI V-infected patients are reviewed.Keywords - Saccharomyces boulardii; Biotherapeutic agent; Clostridium difficile; Diarrhoea.
  • References (78)
    78 references, page 1 of 8

    1. Adam J, Barret A, Barret-Bellet C, et al. (1977). Essais cliniques contrdlks en double insu de l'ultralevure lyophilisee. Etude multicentrique par 25 mkdecins de 388 cas. Gazette Medicale de France 84, 2072-2078.

    2. Aronsson B, Molby R, Nord CE. (1985). Antimicrobial agents and Clostridium dzficile in acute enteric disease: epidemiological data from Sweden. Journal of Infectious Diseases 151,476-48 I .

    3 . Bartlett JG. (1992). Antibiotic-associated diarrhea. Clinical Infectious Diseases 15,573-58 I .

    4. Berg R, Bernasconi P, Fowler D, Gautreaux M. (1993). Inhibition of Candida albicans translocation from the gastrointestinal tract of immunosuppressed mice by oral treatment with Saccharomyces boulardii. Journal oflrtfectious Diseases (in press).

    5 . Blehaut H, Massot J, Elmer GW, Levy RH. (1989). Disposition kinetics of Saccharomyces boulardii in man and rat. Biopharmaceutics & Drug Disposition 10,353-364.

    6. Blehaut H, Saint-Marc T, Touraine JL. (1992). Double blind trial of Saccharomyces boulardii in AIDS related diarrhea. Abstract No. 2120, VIII International Conference on AIDS/III STD World Congress, 19-24 July.

    7. Boddy AV, Elmer GW, McFarland LV, Levy RH. (1991). Influence of antibiotics on the recovery and kinetics of Saccharomyces boulardii in rats. Pharmaceutical Research 8,796-800.

    8. Bowden TA, Mansberger AR, Lykins LE. (1982). Pseudomembraneous enterocolitis: mechanism of restoring floral hemeostasis. American Surgeon 4, I 78- 183.

    9. Buts J-P, Bernasconi P, Van Craynest M-P, Maldague P, De Meyer R. (1986). Response of human and rat smallintestinal mucosa to oral administration of Saccharomyces boulardii. Pediatric Research 20, 192-196.

    10. Buts J-P, Bernasconi P, Vaerman J-P, Dive C. ( I 990). Stimulation of secretory IgA and secretory component of immunoglobulins in small intestine of rats treated with Saccharomyces boulardii. Digestive Diseases and Sciences 35,251-256.

  • Metrics
    No metrics available
Share - Bookmark